Craig-Hallum Maintains Simulations Plus(SLP.US) With Buy Rating
KeyBanc Maintains Simulations Plus(SLP.US) With Buy Rating, Raises Target Price to $40
Simulations Plus Price Target Raised to $40.00/Share From $32.00 by Keybanc
Keybanc Maintains Overweight on Simulations Plus, Raises Price Target to $40
Simulations Plus Analyst Ratings
KeyBanc Reaffirms Their Buy Rating on Simulations Plus (SLP)
A Quick Look at Today's Ratings for Simulations Plus(SLP.US), With a Forecast Between $41 to $65
Analysts Are Bullish on These Healthcare Stocks: Simulations Plus (SLP), Viridian Therapeutics (VRDN)
JMP Securities Maintains Simulations Plus(SLP.US) With Hold Rating
Simulations Plus (SLP) Receives a Hold From JMP Securities
Craig-Hallum Maintains Simulations Plus(SLP.US) With Buy Rating
Craig-Hallum Maintains Simulations Plus(SLP.US) With Buy Rating
Simulations Plus Analyst Ratings
Keybanc Maintains Overweight on Simulations Plus, Raises Price Target to $37
KeyBanc Maintains Simulations Plus(SLP.US) With Buy Rating, Raises Target Price to $37
Simulations Plus Analyst Ratings
BTIG Maintains Simulations Plus(SLP.US) With Buy Rating, Maintains Target Price $50
Oppenheimer Maintains Simulations Plus(SLP.US) With Buy Rating, Maintains Target Price $65
KeyBanc Maintains Simulations Plus(SLP.US) With Buy Rating, Cuts Target Price to $35
KeyBanc Lowers Price Target on Simulations Plus to $35 From $40, Keeps Overweight Rating